Ivermectin-artemisinin Combination Therapy for Eradication of Malaria
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
Malaria remains a leading cause of morbidity and mortality globally. Uganda has the 3rd
highest global burden of malaria cases (5%) and the 7th highest level of deaths (3%),
accounting for over 10,500 deaths annually. Uganda also has the highest proportion of malaria
cases in East and Southern Africa (23.7%). Even with the current prevention strategies
including use of impregnated mosquito nets, in 2017, malaria still accounted for 27-34 % of
outpatient visits, 19-30 % of hospital admissions, up to 20% of all hospital deaths
nationally. A significant percentage of deaths occur at home and are not reported by the
facility-based Health Management Information System (HMIS). 27.2% of inpatient deaths among
children under five years of age are due to malaria. The transmission of Plasmodium from
humans to mosquitoes depends on the presence of mature gametocytes transmission stages. The
current first-line treatment for uncomplicated falciparum malaria is artemether lumefantrine,
an artemisinin combination therapy (ACT) which rapidly clears asexual parasites and
developing gametocytes but leaves mature P. falciparum gametocytes largely unaffected, thus a
proportion of patients may transmit malaria after successful ACT treatment and there is an
urgent need to prevent this malaria transmission.
Phase:
Phase 4
Details
Lead Sponsor:
Makerere University
Treatments:
Artemether Artemether, Lumefantrine Drug Combination Ivermectin Lumefantrine